take today earn
four compani coverag report earn today
lh earli sign recoveri continu
consist theme well telehealth becom
integr part primari care workflow highlight
call
laboratori corp america hold lh
share outperform combin strong underli
result increas confid full year result follow discuss
manag highlight path earn per share delay
elect cost medicaid enrol off-set higher covid cost
quarterli highlight includ ingenio perform ahead expect benefit
stronger covid script volum path medicaid margin improv
progress toward close commerci aso profit gap
relat annual medic cost
relat elect procedur manag see good chanc
procedur spill unemploy seen slight
uptick medicaid enrol state temporarili suspend reverif
effort see sign dis-enrol last week april
acceler lower group enrol expect increas
come month expect half commerci live enrol
medicaid third exchang delay premium collect
april
share outperform continu busi momentum
clariti confid guidanc better medicar
advantag enrol execut pdp strategi key highlight
manag see midpoint guidanc reason jump point
absent higher-than-expect rebat payout unexpect
relat messag call manag
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
take stage approach toward invest resourc support member
benefit invest like back end weight price decis
bid due june incorpor pre-covid trend januari
februari establish base line trend layer expect
covid cost impact revenu code chang relat
get elect procedur volum back elect spend percent medic
cost mid-teen manag see key swing factor
system abil run normal level work demand backlog
consum confid come back healthcar set
share under-perform despit bullish comment covid test
core organ volum pre covid fallout softer well book bill
trend normal organ volum exhibit softer consid
easier y/i compar book bill
quarter lowest sinc bright spot price
covid pcr serolog test focal point lh earn
call pcr capac test day manag hope get
may run full capac economi open
serolog test capac current test day well
mid-may ultim uptick depend avail point
care solut util guidelin employ incorpor back
work plan whether test need done twice way manag
lower sensit combin drug develop diagnost
capabl translat labcorp win nearli twice share
relat vaccin antivir trial
guidanc adjust earn call struck bullish tone
largest revenu headwind servic legaci revenu
expect account total annual revenu
manag look servic activ catch-up client return
normal pattern busi
sale cycl life scienc provid vertic elong
somewhat pipelin remain healthi among payor pharmaci client
manag see near-term opportun client focu data analyt
capabl especi address covid question addit long-term
opportun shift provid model adopt telehealth
shift regulatori stanc reimburs telehealth
read thru healthcar compani
see procedur skew toward
outpati procedur set come back sooner ex
neuromodul procedur favor trend mco
univers health system expect elect volum fulli
return may-juli period doesnt expect mix shift
hospit outpati set term type procedur
pacemak cardiac catheter oncolog surgeri neurosurgeri
heavy-duti orthoped surgeri like come back sooner
discretionari cosmet ophthalmolog procedur like
push outright cancel
teladoc see visit first-tim user histor
lower-util year old male medicaid
milliman host webcast today estim impact
healthcar cost latest analysi quantifi net reduct
medic cost billion much billion deferr
care continu end commerci medicar
payor like see net reduct cost medicaid payor could
experi net increas peopl lost job shift
safeti net program
addit color earn call
ingenio perform ahead expect ingenio earn million ahead
expect prior manag commentari suggest million earn
per quarter billion net save move contract drop
bottom line annual basi million million million beat
driven segment shift aso pbm busi commerci specialti
ingenio report bucket remain million million due
stronger perform higher covid script volum look rest year
earn like lower per quarter busi mix shift due chang
economi script declin high regard sell season
manag believ strong pipelin opportun expect defer
decis make employ deal covid consist check
medicaid margin track aso margin progress medicaid margin track
end rate action quarter in-lin expect
rate action happen compani strong visibl
perform remaind year confid hit midpoint
target margin rang progress toward improv aso profit remain
track prior covid though rfp activ decreas year slow
progress aso risk profit manag see path
profit year progress move past covid
price action book renew januari suggest signific mid-
year renew near-term compani gain clariti covid dynam
come month believ suffici time develop inform
bid commerci price final october/novemb time-frame
enrol track ahead expect individu medicar advantag
membership expect add addit member vs
prior guidanc member add result higher sale better
retent expect prior covid individu pmpm premium util
trend favor origin expect new
pdp strategi play first quarter experienc similar dynam fourth quarter
strong enrol trend compani new low premium plan wal-mart valu
rx dis-enrol premier rx plan premium increas see note
pdp landscap heat plan comparison enrol pdp plan
gener declin peopl move plan present compani
strong funnel member convert
guidanc lower account covid impact sale cycl servic
full-year revenu guidanc million
million prior impli y/i growth y/i midpoint vs
prior million decreas full-year guidanc compos million
miss million lower revenu million lower
revenu split across
top-line miss attribut shortfal servic legaci revenu
impact expect sever experienc million shortfal
servic legaci revenu vs manag intern expect expect see
doubl impact million drag servic legaci revenu revenu
guidanc million impli y/i growth midpoint vs
prior impli growth guidanc impli guidanc in-lin
street manag expect top-line growth
prior sequenti y/i growth contract
earlier year begin implement servic resum normal level
book expect rebound acv quarter
million declin y/i sequenti result sale elong
life scienc provid market given client near-term focu address
covid howev manag note sale pipelin remain healthi among payor
pharmaci client
ebitda guidanc million million prior
impli margin in-lin prior guidanc manag note
compani exercis prudenc come cost control invest
sale rep expans continu track result revenu declin ep guidanc
prior
updat estim rase price target rase ep
estim rais price target due
increas benefit relat pcr serolog test
execut growth ingeniorx integr medicaid margin upsid
calcul price target appli price-to-earnings multipl base case ep
multipl reect turn discount multipl in-lin
compani year averag discount adjust hif repeal period
fear weigh multipl
largest commerci player
market share second largest
player medicaid exchang
helm new ceo gail
boudreaux anthem focus
improv commerci busi
protabl gain share medicar
advantag market place current
insourc pbm accret earn
posit anthem effect
compet marketplac
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
ep
bull case multipl reect premium
bull case multipl reect premium
multipl
multipl reect year
averag discount adjust
hif repeal
ep
multipl
multipl multipl in-
line compani year averag
discount adjust hif repeal
period fear weigh
multipl
ep
discount current multipl
discount current multipl
discount trade
trough last industri price
cycl adjust hif repeal
failur execut pbm transit result
lost prot opportun enrol
view explan region hierarchi
research highest favor quintil
medicar advantag growth market
pbm transit poorli execut result
lower protabl lost member
price pressur govern
commerci busi result margin
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
return histor growth optum epicent earn potenti
calcul price target appli price-to-earnings multipl base case ep
multipl reect turn premium multipl in-lin
year averag premium histor trade adjust repeal hif
period fear weigh multipl believ
outcom like
number one
medicar advantag player
market share number two medicar
pdp player market share
number two commerci player
unit model enhanc via vertic
integr optumrx pbm platform
one three largest pbm
countri
larg lead breadth servic
offer consider exposur
govern busi well
posit potenti chang
strong balanc sheet continu
solid cash gener give exibl
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
view descript risk reward theme
ep
bull case multipl reect premium
bull case multipl reect premium
multipl
multipl premium in-lin
year averag peak adjust
discount repeal hif
ep
premium multipl
premium multipl
premium in-lin year averag
premium histor trade
adjust repeal hif
period fear
weigh multipl believ
outcom like
ep
multipl
multipl discount in-
line stock trade trough
last price cycl
adj hif repeal
optum margin esp optumrx
view explan region hierarchi
research highest favor quintil
growth market
optum integr lead industri lead
medicaid margin improv target
slower growth core growth area
medicar advantag commerci medicaid
focu servic
optum growth slow competitor becom
reluct work unitedhealth
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
calcul price target appli price-to-earnings multipl base case ep
multipl reect premium multipl in-lin
year averag premium adjust repeal hif estimate period
multipl weigh see like scenario
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
high earn exposur
medicar advantag
execut organ medicaid
growth earn
medicaid provid addit growth
pipelin copmani
recent medicaid contract win la
ky underscor manag medicaid
strategi play
strong balanc sheet continu
solid cash gener lay foundat
view descript risk reward theme
ep
bull case multipl reect premium
bull case multipl reect premium
multipl
multipl in-lin
compani year averag peak
premium
ep
base case multipl reect premium
base case multipl reect premium
multipl
multipl reect
year averag premium adjust repeal
hif estimate period
multipl weigh
see like scenario
ep
bear case multipl reect discount
bear case multipl reect discount
current multipl
current multipl
in-lin discount
last price cycl
adjust hif repeal
 strateg ventur leverag footprint
enhanc valu base offer
view explan region hierarchi
research highest favor quintil
abl grow medicaid busi
rfp win tuck-in
compani abl sustain market
margin improv target rang
unabl maintain recent
improv star rate
competit medicar advantag
make growth challeng
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
custom renew visibl revenu acv trend support pt
multiples-bas price target assum multipl ebitda in-lin
averag ev/ebitda multipl softwar compani grow top-line
hsd-ldd ebitda margin rang
inovalon provid cloud-bas
healthcar manag care organ
provid pharmaci life scienc
expect top-line organ growth
hsd-ldd rang contract
renew rate rang
revenu come subscript
increas visibl futur revenu
expect platform invest
oper efcienc continu drive
ebitda growth margin expans
slightli off-set invest sale
view descript risk reward theme
bull case ebitda
ev/ebitda multipl appli
ev/ebitda multipl appli
bull case ebitda estim
bull case ebitda estim
million revenu acceler mid-teen
ebitda margin improv high-
base case ebitda
ev/ebitda multipl appli
ev/ebitda multipl appli
base case ebitda estim
base case ebitda estim
million revenu growth remain hsd-
ldd ebitda margin remain mid-
bear case ebitda
ev/ebitda multipl appli
ev/ebitda multipl appli
bear case ebitda estim
bear case ebitda estim
million revenu growth declin mid-
singl digit ebitda margin remain
rang
acceler acv
view explan region hierarchi
research highest favor quintil
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
risk reward laboratori corp america hold lh
lt share gain opp pref payor partnership cro faster growth
multipl appli core earn power
multipl appli core earn power multipl deriv current
multipl minu lh year averag discount
multipl appli covid earn power
multipl appli covid earn power multipl base
compani core multipl plu averag pe multipl expans sinc
market trough rel pseen covid test compani
includ
labcorp second largest refer
lab compani matur industri
plan open lab
contract establish long-term strateg
partnership labcorp quest
diagnost set stage ration
price share gain opportun
posit lab rel safe haven
within hc servic sector
headwind
reimburs pressur exposur
quanti factor ms/market
cro diversi labcorp busi
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
pt base sum part
multipl appli bull case ep
multipl appli bull case ep
multipl deriv current multipl
plu lh year peak discount
pt base sum part
multipl appli core earn
multipl appli core earn
power
power multipl deriv
current multipl minu lh
year averag discount
pt base sum part
multipl appli bear case ep
multipl appli bear case ep
multipl deriv current multipl
minu lh year trough discount
multipl appli covid earn
multipl appli covid earn
power
power multipl base
compani core multipl plu
sinc market trough rel
 pseen covid test
multipl appli covid earn
multipl appli covid earn
power
power multipl base
compani core multipl plu
sinc market trough rel
 pseen covid test
multipl appli covid earn
multipl appli covid earn
power
power multipl base
compani core multipl plu
sinc market trough rel
 pseen covid test
 risk reward laboratori corp america hold lh
laboratori corpor america hold
laboratori corpor america hold
volum growth less scale region
player prefer lab network
china india
view explan region hierarchi
research highest favor quintil
higher core volum growth faster
expect share gain region
revers pama cut
medicar reimburs pressur
abat revers
covanc chiltern deal synergi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
